Novartis AG has presented detailed data on its latest multiple sclerosis drug ofatumumab which the company believes will provide a more convenient treatment for patients than Roche's rival therapy Ocrevus.
Having published positive topline results last month, Novartis presented the full data set from the Phase III ASCLEPIOS I and...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
